Envoy Medical Completes Pivotal Trial Enrollment, Reports Positive Early Data, and Secures $30M Capital

summarizeSummary

Envoy Medical announced the completion of enrollment in its pivotal clinical trial for the Acclaim cochlear implant and reported promising early clinical data, alongside a strengthened cash position from a recent $30 million capital raise.

check_boxKey Events

• Pivotal Trial Enrollment Completed

  Envoy Medical successfully completed enrollment of 56 patients in its U.S. pivotal clinical trial for the Acclaim® cochlear implant on March 11, 2026, a critical step towards FDA Premarket Approval (PMA).

• Positive Early Clinical Data Reported

  Interim six-month data from the first 10 patients showed no serious adverse events and significant improvement in word recognition scores (from 15.2% to 39.2%), along with improvements in quality-of-life and tinnitus scores.

• Strengthened Cash Position

  The company reported a cash balance of approximately $25.25 million as of March 31, 2026, a substantial increase from $3.74 million at year-end 2025, following a $30 million capital raise.

• Advancing Towards Commercialization

  All 56 pivotal trial patients have been activated, and the first three patients have completed their 12-month endpoint visits, keeping the company on track for PMA submission.

auto_awesomeAnalysis

This filing is critical as Envoy Medical, a company previously facing a 'going concern' warning, has achieved major milestones. The completion of enrollment in its pivotal clinical trial for the Acclaim cochlear implant and the presentation of positive interim 6-month data significantly de-risk its path to FDA approval and potential commercialization. Furthermore, the $30 million capital raise has substantially improved its cash position to $25.25 million, providing crucial runway to fund operations and advance the clinical program. This combination of clinical progress and financial stability is a strong positive for the company's future.